Generate Biomedicines

Forecast & Rating6 analysts currently cover Generate Biomedicines, with about 100.0% giving a positive rating — meaning they expect the stock to rise. The average price target is $25.40, about 85.9% upside from the current price of $13.67. Price targets span a fair range, indicating some disagreement among institutions. For you, this means most professionals who study Generate Biomedicines closely still see room for the stock to rise. Data as of May 14, 2026; for reference only and not investment advice.